November 29, 2007 – Confirma announced that a study by the Seattle Cancer Care Alliance and the University of Washington presented at RSNA suggests that the CADstream system’s patented “worst curve” algorithm for analyzing kinetics may assist in determining malignancy.
The study, “MRI Detected Suspicious Breast Findings: Comparison of Kinetic Features Measured by Computer-aided Evaluation in Benign and Malignant Lesions”, was led by Dr. Lilian Wang, M.D., radiology resident at the Seattle Cancer Care Alliance and University of Washington. It focused on the evaluation of kinetics and found that the most suspicious curve as identified by CADstream was significantly different between benign and malignant lesions. This supports the recommendation of the American College of Radiology’s Breast Imaging Reporting and Database System (BI-RADS) Atlas for breast MRI to report the “worst looking” curve. The study found that any washout enhancement was associated with malignancy in nearly half of lesions.
The study retrospectively examined 125 suspicious lesions (42 malignant, 83 benign) for which CADstream’s computer-aided evaluation and subsequent image-guided biopsy had been performed, out of a pool of 1538 breast MRI examinations conducted from November 2004 to November 2006. The study compared three distinct computer-aided-evaluation kinetic features of suspicious breast MRI lesions to determine which could best predict benign or malignant outcomes. The study concluded that of the kinetic features analyzed only the most suspicious curve type as identified by CADstream was significantly different between benign and malignant lesions.
“Our findings are consistent with the ACR BI-RADS Atlas recommendation for reporting the ‘worst looking kinetic curve’ of a lesion with breast MRI,” said Dr. Wang.
The CADstream system automates analysis, reporting and interventional planning of studies and promotes standardization with the incorporation of the American College of Radiology’s Breast Imaging Reporting and Database System (BI-RADS), which guides the breast cancer diagnostic routine and decision-making process. Confirma’s next-generation version of CADstream for breast MRI, launched at the RSNA meeting, includes a new customizable BI-RADS-centric user interface that accommodates a variety of user experience levels. Additional CADstream enhancements include improved 3D renderings and tools for morphology reporting.
For more information: www.confirma.com